Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$116.17 - $194.55 $313,659 - $525,285
-2,700 Reduced 18.88%
11,600 $1.35 Million
Q1 2021

May 17, 2021

BUY
$124.11 - $190.17 $1.3 Million - $2 Million
10,500 Added 276.32%
14,300 $1.89 Million
Q4 2020

Feb 16, 2021

SELL
$112.16 - $174.14 $1.03 Million - $1.6 Million
-9,200 Reduced 70.77%
3,800 $658,000
Q2 2020

Aug 14, 2020

SELL
$57.2 - $74.41 $308,880 - $401,814
-5,400 Reduced 29.35%
13,000 $771,000
Q1 2020

May 15, 2020

BUY
$57.05 - $95.75 $844,340 - $1.42 Million
14,800 Added 411.11%
18,400 $1.24 Million
Q4 2019

Feb 14, 2020

SELL
$68.3 - $93.8 $1.86 Million - $2.56 Million
-27,300 Reduced 88.35%
3,600 $303,000
Q3 2019

Nov 14, 2019

BUY
$61.86 - $97.8 $1.66 Million - $2.63 Million
26,900 Added 672.5%
30,900 $2.31 Million
Q2 2019

Aug 14, 2019

BUY
$42.22 - $63.23 $168,880 - $252,920
4,000 New
4,000 $253,000

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $1.79B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.